
    
      This Phase 2/3 efficacy study is designed as a double-blind, randomized, placebo-controlled
      study.

      This is a 12-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of
      patients with RTT 5-18 years of age. A voluntary option will be offered for all patients who
      meet the exposure criteria for ANAVEX2-73 to continue a 48-week open label extension.
    
  